Literature DB >> 7651043

Dipyridamole augmentation of response to nitric oxide.

J P Kinsella, F Torielli, J W Ziegler, D D Ivy, S H Abman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7651043     DOI： 10.1016/s0140-6736(95)91487-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Therapies that enhance pulmonary vascular NO-signaling in the neonate.

Authors:  Julie Dillard; Marta Perez; Bernadette Chen
Journal:  Nitric Oxide       Date:  2019-12-20       Impact factor: 4.427

Review 2.  Inhaled nitric oxide in neonates.

Authors:  N Finer
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-09       Impact factor: 5.747

3.  The use of phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide.

Authors:  S al-Alaiyan; A al-Omran; D Dyer
Journal:  Intensive Care Med       Date:  1996-10       Impact factor: 17.440

4.  Selective type 5 phosphodiesterase inhibition alters pulmonary hemodynamics and lung liquid production in near-term fetal lambs.

Authors:  Robert C Dukarm; Robin H Steinhorn; James A Russell; Satyan Lakshminrusimha; Daniel Swartz; James J Cummings
Journal:  J Appl Physiol (1985)       Date:  2005-08-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.